Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Vertex Pharmaceuticals Incorporated (VRTX) had Stock-Based Compensation of $166.10M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$2.77B |
|
$646.30M |
|
$363.00M |
|
$2.41B |
|
$2.14B |
|
$630.10M |
|
$100.30M |
|
$730.40M |
|
$730.40M |
|
$646.30M |
|
$646.30M |
|
$646.30M |
|
$646.30M |
|
$630.10M |
|
$678.50M |
|
256.90M |
|
259.50M |
|
$2.52 |
|
$2.49 |
|
| Balance Sheet Financials | |
$10.01B |
|
$1.30B |
|
$12.87B |
|
$22.88B |
|
$3.78B |
|
$111.40M |
|
$2.60B |
|
$6.38B |
|
$16.50B |
|
$14.97B |
|
$16.50B |
|
256.97M |
|
| Cash Flow Statement Financials | |
$818.90M |
|
$-55.80M |
|
$-680.40M |
|
$4.57B |
|
$4.69B |
|
$113.20M |
|
|
Stock-Based Compensation |
$166.10M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.65 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
86.90% |
|
22.75% |
|
22.75% |
|
-- |
|
26.37% |
|
23.33% |
|
$778.20M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.27 |
|
1.53 |
|
58.65 |
|
3.92% |
|
4.32% |
|
2.82% |
|
3.89% |
|
$64.20 |
|
$3.00 |
|
$3.16 |
|